Surrozen (SRZN) CFO Maleki Andrew Pedrum Buys $12K of Stock

On June 15, 2026, Andrew Pedrum Maleki, the Chief Financial Officer of Surrozen, Inc., purchased 607 shares of the company's stock. He bought the shares at an average price of $19.01, for a total transaction value of $11,539.07. This insider purchase comes as Surrozen's stock trades at $23.14 on the Nasdaq Capital Market.

Insider Buying and Selling at Surrozen, Inc.

In addition to CFO Andrew Pedrum Maleki's purchase, other insiders at Surrozen also bought shares on June 15, 2026. Charles Williams, the Chief Operating Officer, and Craig Parker, the Chief Executive Officer, each acquired 1,666 shares at $8.11 per share. Similarly, Yang Li, the Executive Vice President of Research, purchased 1,666 shares at the same price. Earlier, on May 13, 2026, Tim Kutzkey and Mary Haak-Frendscho each acquired 5,550 shares, though the transaction price was not disclosed.

Other Institutional Activity in Surrozen, Inc.

Several institutional investors adjusted their positions in Surrozen. COLUMN GROUP LLC increased its holdings by 65,600 shares, bringing its total to 1,916,950 shares valued at approximately $55.8 million. TCG CROSSOVER MANAGEMENT, LLC acquired 1,473,101 shares, now holding shares worth about $42.9 million. BOXER CAPITAL MANAGEMENT, LLC significantly boosted its stake by 350,168 shares, ending with 766,318 shares valued at $22.3 million. Meanwhile, STEMPOINT CAPITAL LP reduced its position by 94,127 shares, holding 525,639 shares worth around $13.5 million.

Surrozen, Inc. Stock Up 37.5%

Shares of Surrozen, Inc. (NasdaqCM:SRZN) are trading at approximately $23.14. The company, with a market capitalization of $264.1 million, operates in the biotechnology sector. Surrozen's stock has seen a 52-week low of $8.00 and a high of $35.00. The company's forward P/E ratio is not meaningful as it is not currently profitable, and it has a beta of 0.506. The stock's 50-day moving average is $27.95, and its 200-day moving average is $21.21.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for Surrozen. On May 7, 2026, HC Wainwright & Co. maintained its 'buy' rating and set a price target of $44.00. Earlier, on March 24, 2026, the same firm reiterated its 'buy' rating with a $36.00 target. Cantor Fitzgerald initiated coverage on February 19, 2026, with a 'buy' rating and a $40.00 price target. The consensus among analysts is a 'buy' rating, with an average target price of $42.50 from four analyst opinions.

About Surrozen, Inc.

Surrozen, Inc. is a biotechnology company based in South San Francisco, California. It focuses on discovering and developing therapeutic candidates that selectively modulate the Wnt pathway, aiming to repair tissues. The company's lead products include antibody-based therapeutics targeting diseases like diabetic macular edema and age-related macular degeneration. Surrozen collaborates with Boehringer Ingelheim and TCGFB, Inc. to advance its research and development efforts.

Bottom Line

The insider purchase by Surrozen's CFO reflects a personal investment in the company's future. Investors often watch such insider activities for potential insights into management's confidence. However, it's important to remember that these transactions are disclosed after the fact. Surrozen remains a company of interest in the biotechnology sector, with ongoing developments and analyst support.